Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
BridgeBio Oncology Therapeutics Inc (BBOT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.30-0.86%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for BBOT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Develop BBO-11818 and BBO-10203 combinations in KRAS-mutant cancers | A supporting condition in BridgeBio Oncology Therapeutics Inc's published investment case. The stated target is data updates for BBO-11818 expected in Q4 2026. | Intact | data updates for BBO-11818 are delayed beyond Q4 2026 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
BBOT is a speculative clinical-stage biotechnology business, where future progress depends on experimental treatments advancing through clinical development. Its thesis is in a watch state: management has set new development priorities, but recent financial performance is weak and confidence in the overall assessment is low.
The evidence does not provide a valuation level or clear account of market expectations, so whether BBOT is cheap or expensive versus peers is unclear. No priced-in fragility concerns were flagged, but that does not resolve the uncertainty around expectations.
Near term, repeated earnings misses and an elevated risk of another miss point to continued uncertainty; the risk label recently moved from elevated to high. Over the multi-year view, $344.1 million in cash as of 2026-Q2 is expected to fund operations into 2028, while management advances its KRAS-focused programs and awaits clinical data milestones.
The thesis depends on clinical progress, including updates for BBO-11818 and BBO-10203 expected in Q4 2026 and mid-2027, and on whether BBO-8520 combination results support further development. Near term, weakening jobs data could weigh on cyclical healthcare names, while continued strength or weakness among sector bellwethers could reinforce or reduce the sector tailwind.
For the next one to three years, BBOT has meaningful clinical milestones and stated cash runway, but weak recent performance, high risk, and low evidence confidence leave the long-term thesis uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in a supplied disclosure. Management reported: ““Across our portfolio, all three programs have now generated encouraging clinical data supporting further development, enabling us to focus our capital on the opportunities with the highest probability of success, clearest development paths, and greatest potential patient benefit,” said Pedro J.”
Advance BBO-8520 in combination with pembrolizumab for 2L+ NSCLC | A primary condition in BridgeBio Oncology Therapeutics Inc's published investment case. The stated target is >=75% overall response rate. | Intact | overall response rate falls below 75% | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in a supplied disclosure. Management reported: ““Across our portfolio, all three programs have now generated encouraging clinical data supporting further development, enabling us to focus our capital on the opportunities with the highest probability of success, clearest development paths, and greatest potential patient benefit,” said Pedro J.” Delivery assessment Nov 4, 2026 |
Maintain strong financial position with cash runway into 2028 | A supporting condition in BridgeBio Oncology Therapeutics Inc's published investment case. The stated target is cash runway into 2028. | Intact | cash position falls below $344 million | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in a supplied disclosure. Management reported: ““Across our portfolio, all three programs have now generated encouraging clinical data supporting further development, enabling us to focus our capital on the opportunities with the highest probability of success, clearest development paths, and greatest potential patient benefit,” said Pedro J.” Delivery assessment Nov 4, 2026 |
Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.48 → $-2.52 · observed estimates
$0.03B → $0.03B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-09-07 | $-2.48 | $29,051,857 | 7 / 9 |
| 2026-09-08 | $-2.48 | $29,051,857 | 7 / 9 |
| 2026-09-09 | $-2.48 | $29,051,857 | 7 / 9 |
| 2026-09-10 | $-2.48 | $29,051,857 | 7 / 9 |
| 2026-09-11 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-09-12 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-09-13 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-09-14 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-09-15 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-09-16 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-09-17 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-09-18 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-09-19 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-09-20 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-09-21 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-09-22 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-09-23 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-09-24 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-09-25 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-09-26 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-09-27 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-09-28 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-09-29 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-09-30 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-10-01 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-10-02 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-10-03 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-10-04 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-10-05 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-10-06 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-10-07 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-10-08 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-10-09 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-10-10 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-10-11 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-10-12 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-10-13 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-10-14 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-10-15 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-10-16 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-10-17 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-10-18 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-10-19 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-10-20 | $-2.49 | $29,051,857 | 7 / 9 |
| 2026-10-21 | $-2.51 | $29,051,857 | 7 / 9 |
| 2026-10-22 | $-2.52 | $29,051,857 | 7 / 9 |
| 2026-10-23 | $-2.52 | $29,051,857 | 7 / 9 |
| 2026-10-24 | $-2.52 | $29,051,857 | 7 / 9 |
| 2026-10-25 | $-2.52 | $29,051,857 | 7 / 9 |
| 2026-10-26 | $-2.52 | $29,051,857 | 7 / 9 |
| 2026-10-27 | $-2.52 | $29,051,857 | 7 / 9 |
| 2026-10-28 | $-2.52 | $29,051,857 | 7 / 9 |
| 2026-10-29 | $-2.52 | $29,051,857 | 7 / 9 |
| 2026-10-30 | $-2.52 | $29,051,857 | 7 / 9 |
| 2026-10-31 | $-2.52 | $29,051,857 | 7 / 9 |
| 2026-11-01 | $-2.52 | $29,051,857 | 7 / 9 |
| 2026-11-02 | $-2.52 | $29,051,857 | 7 / 9 |
| 2026-11-03 | $-2.52 | $29,051,857 | 7 / 9 |
| 2026-11-04 | $-2.52 | $29,051,857 | 7 / 9 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 12 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 2 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.